Aarti Pharmalabs Ltd.

823.65-5.1 (-0.62%)

23 Oct, 12:00 AM

Income Statement

Abridged

Understanding Income Statement

Aarti Pharmalabs Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M IR	12M IR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	-	1,200	1,945	1,853	2,115	1,819	1,969
Cost of Operating Revenue	-	767	1,232	1,094	1,215	939	1,014
Gross Profit	-	433	713	759	900	880	955
Gross Margin	-	36.1	36.7	41.0	42.6	48.4	48.5
Total Operating Expenses	0	879	1,665	1,540	1,738	1,521	1,641
Operating Profit	0	321	280	313	377	298	328
Operating Margin	-	26.7	14.4	16.9	17.8	16.4	16.7
Financing Income/(Expense) - Net	-	-9	-19	-14	-18	-78	-83
Profit before Taxes	0	155	261	300	361	233	269
Income Taxes	-	33	67	84	88	58	67
Profit after Tax	0	122	193	217	272	175	201
PAT Margin	-	10.2	9.9	11.7	12.9	9.6	10.2
EPS - Basic - ex Extraordinary Items	0.00	13.49	21.35	23.93	30.06	19.27	22.20
EPS - Diluted - ex Extraordinary Items	0.00	13.49	21.35	23.93	30.06	19.25	22.02
EBIT	0	321	280	313	377	298	328
EBITDA	0	363	342	386	464	403	440
EBITDA Margin	-	30.2	17.6	20.8	22.0	22.1	22.3

Balance Sheet

Abridged

Understanding Balance Sheet

Aarti Pharmalabs Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
Source:	IR	IR	AR	AR	AR	AR
Total Current Assets	0	1,028	1,156	1,346	1,318	1,397
Long-Term Investments	-	32	36	37	29	194
Property Plant & Equipment - Net	-	945	986	1,093	1,411	1,707
Total Non-Current Assets	-	1,012	1,075	1,236	1,584	2,084
Total Assets	0	2,040	2,231	2,582	2,902	3,482
Total Current Liabilities	0	581	592	694	653	938
Long Term Debt	-	2	1	17	123	253
Total Non-Current Liabilities	-	73	81	131	259	420
Total Liabilities	0	653	672	825	913	1,357
Total Shareholders' Equity	0	1,386	1,558	1,757	1,990	2,125
Total Equity	0	1,386	1,558	1,757	1,990	2,125
Total Liabilities & Equity	0	2,040	2,231	2,582	2,902	3,482

Cash Flow

Abridged

Understanding Cash Flow Statement

Aarti Pharmalabs Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	2024 Mar 31	C 2025 Mar 31	2026 Mar 31
	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	2024 Mar 31	C 2025 Mar 31	2026 Mar 31
Period length: Source:	12M IR	12M IR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	0.00	177.19	261.67	324.06	399.08	332.29
Working Capital - Increase/(Decrease)	0.00	-230.36	-31.63	-121.85	-86.31	-106.96
Net CF from Operating Activities	-	-53.17	230.04	202.21	312.77	225.34
Capital Expenditures - Net	-	141.15	119.66	198.79	443.88	448.31
Net CF from Investing Activities	-	-141.23	-158.78	-217.64	-419.62	-432.86
Dividends Paid - Cash - Total	-	-	18.13	18.13	31.72	36.26
Stock - Issuance/(Retirement) - Net	-	-	-	-	0.00	0.01
Debt - LT & ST - Issuance/(Retirement) - Total	-	272.34	-124.29	45.06	121.66	245.56
Net Cash Flow from Financing Activities	-	272.34	-142.41	26.94	89.95	209.32
Free Cash Flow to Equity	-	78.02	-13.90	48.49	-9.44	22.59
Free Operating CF net dividend	-	-194.33	92.26	-14.70	-162.82	-259.24
Free Operating CF	-	-194.33	110.38	3.43	-131.10	-222.98

Business Segment Analysis

FY End:

Mar 26

Aarti Pharmalabs Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Home and personal care ingredients (100.0%)₹ 448.31 Cr

Revenue / Sales

Home and personal care ingredients (100.0%)₹ 1,819.44 Cr

Assets

Home and personal care ingredients (100.0%)₹ 3,481.71 Cr

Operating Income

Home and personal care ingredients (100.0%)₹ 298.08 Cr

Regional Segment Analysis

Aarti Pharmalabs Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Aarti Pharmalabs Ltd.

Historical Segment Analysis

Track how Aarti Pharmalabs Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Home and personal care ingredients	120	199	444	448

Frequently Asked Questions

What is the revenue of Aarti Pharmalabs Ltd.?

The latest trailing twelve month revenue of Aarti Pharmalabs Ltd. is ₹ 1,969.05 Cr, reflecting a 1-year growth of 1.20% and a 3-year CAGR of 0.39%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Aarti Pharmalabs Ltd.?

The latest trailing twelve month net profit (PAT) of Aarti Pharmalabs Ltd. is ₹ 213.15 Cr, with a 3-year earnings CAGR of 3.97%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Aarti Pharmalabs Ltd.?

The trailing twelve month EBITDA of Aarti Pharmalabs Ltd. is approximately ₹ 328.22 Cr (based on an operating margin of 16.67%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Aarti Pharmalabs Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Aarti Pharmalabs Ltd. is 23.50. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Aarti Pharmalabs Ltd.?

The debt-to-equity ratio of Aarti Pharmalabs Ltd. stands at 0.37. The interest coverage ratio is 6.19x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Aarti Pharmalabs Ltd.?

The estimated book value per share of Aarti Pharmalabs Ltd. is 234.30 (derived from a P/B ratio of 3.52 and market price of ₹ 823.65), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Aarti Pharmalabs Ltd.?

The trailing twelve month operating cash flow of Aarti Pharmalabs Ltd. is ₹ 225.34 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Aarti Pharmalabs Ltd. report consolidated or standalone financials?

Aarti Pharmalabs Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.